XML 67 R34.htm IDEA: XBRL DOCUMENT v3.23.3
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
performance_obligation
material_right
Apr. 30, 2018
USD ($)
option
milestone
Sep. 30, 2023
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Accounts receivable     $ 1,148 $ 1,148 $ 3,678
Kite Pharma, Inc. | Change In Agreement Estimate, March 2023          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Increase in revenue       8,900  
Decrease in net loss       $ 8,900  
Increased earnings per share, basic (in dollars per share) | $ / shares       $ (0.05)  
Increased earnings per share, diluted (in dollars per share) | $ / shares       $ (0.05)  
Kite Pharma, Inc. | Change In Estimate, September 2023          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Increase in revenue     4,900 $ 4,900  
Decrease in net loss     $ 4,900 $ 4,900  
Increased earnings per share, basic (in dollars per share) | $ / shares     $ (0.03) $ (0.03)  
Increased earnings per share, diluted (in dollars per share) | $ / shares     $ (0.03) $ (0.03)  
Kite Pharma, Inc. | License and Service          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Remaining performance obligation amount, related to material rights     $ 1,500 $ 1,500 1,500
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Remaining performance obligation amount         $ 21,200
Remaining performance obligation, expected timing of satisfaction period         12 months
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Remaining performance obligation amount     $ 1,500 $ 1,500  
Remaining performance obligation, expected timing of satisfaction period     12 months 12 months  
Kite Pharma, Inc. | License          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability   $ 150,000      
Number of remaining performance obligations | performance_obligation 4        
Number of material rights for renewal of research period | material_right 2        
Renewal period 1 year        
Fixed consideration $ 150,000        
Kite Pharma, Inc. | Collaboration And License Agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Milestone payments received   $ 150,000      
Initial research term of agreement   6 years      
Number of options to extend initial research term | option   2      
Extended research term of agreement   1 year      
Separate fee for additional term   $ 10,000      
Contract with customer liability     $ 1,500 $ 1,500 $ 19,400
Accounts receivable     $ 200 $ 200 $ 700
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contingent development and sales-based milestone payments to be received   1,300,000      
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contingent development and sales-based milestone payments to be received   $ 1,800,000      
Maximum amount of achieved milestones to receive payment | milestone   10      
Kite Pharma, Inc. | Collaboration And License Agreement | Maximum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Development and sales-based milestone payments to be received   $ 3,000,000